The Health Resources and Services Administration (HRSA) administers section 340B of the Public Health Service Act (PHSA), known as the ``340B Drug Pricing Program'' or the ``340B Program.'' HRSA published a final rule on January 5, 2017, that set forth the calculation of the ceiling price and application of civil monetary penalties. The final rule applied to all drug manufacturers that are required to make their drugs available to covered entities under the 340B Program. On May 7, 2018, HHS solicited comments on further delaying the effective date of the January 5, 2017, final rule to July 1, 2019. HHS proposed this action to allow a more deliberate process of considering alternative and supplemental regulatory provisions and to allow for sufficient time for any additional rulemaking. After consideration of the comments received on the proposed rule, HHS is delaying the effective date of the January 5, 2017, final rule, to July 1, 2019.
Document
340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation
The Health Resources and Services Administration (HRSA) administers section 340B of the Public Health Service Act (PHSA), known as the ``340B Drug Pricing Program'' or the ``340...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
83 FR 25943
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation,” thefederalregister.org (June 5, 2018), https://thefederalregister.org/documents/2018-12103/340b-drug-pricing-program-ceiling-price-and-manufacturer-civil-monetary-penalties-regulation.